Lung Cancer Diagnostics Market Size, Share and Trends 2024 to 2034

Lung Cancer Diagnostics Market Size and Forecast 2024 to 2034

The global lung cancer diagnostics market size accounted for USD 5.02 billion in 2024 and is anticipated to reach around USD 9.45 billion by 2034, expanding at a CAGR of 6.53% between 2024 and 2034. surge in active smokers and unhealthy lifestyles is the key factor driving the growth of the market. Also, the increasing demand for innovative diagnostic tools and services in imaging technologies like CT scans can fuel market growth further.

Lung Cancer Diagnostics Market Key Takeaways

• North America dominated the lung cancer diagnostics market with the largest market share of 47.33% in 2023.
• By type, the non-small cell lung cancer (NSCLC) segment led the lung cancer diagnostics market in 2023.
• By type, small-cell lung cancer (SCLC) is expected to grow at the fastest rate over the forecast period.
• By test, the EGFR mutation tests segment dominated the lung cancer diagnostics market in 2023.
• By test, the HER2 test segment is anticipated to grow at the fastest rate during the forecast period.
• By end use, the hospitals and clinics segment has held the major market share of 49% in 2023.
• By end use, the diagnostic laboratories segment is anticipated to show the fastest growth over the projected period.

U.S. Lung Cancer Diagnostics Market Size and Growth 2024 to 2034

The U.S. lung cancer diagnostics market size is estimated at USD 5.02 billion in 2024 and is expected to be worth around USD 9.45 billion by 2034, growing at a CAGR of 6.53% from 2024 to 2034.

North America dominated the lung cancer diagnostics market in 2023. The dominance of the region can be attributed to the developed healthcare infrastructure, extensive reimbursement regulations, and high healthcare spending for diagnosis of cancer. Moreover, the healthcare industry in the region has experienced an increase in patient pool, due to poor diet habits, unhealthy lifestyles, and growing cases of stage-IV lung cancer in many individuals.

• In January 2023, Agilent Technologies Inc. partnered with Quest Diagnostics to improve the accessibility of the Resolution ctDx FIRST test. The test helps to identify advanced NSCLC patients.

Asia Pacific region is expected to show significant growth over the studied period. The growth of the region can be credited to the increasing adoption of innovative diagnostics technologies and growing prevalence of lung cancer in the region. Furthermore, the market is ready to expand because of awareness programs arranged by healthcare organizations and government for early cancer detection.

• Public health initiatives and increased awareness about the importance of early detection are leading to more screening programs, boosting market demand.

Market Overview

Lung cancer is a type of tumour that emerges in the tissues of the lungs typically in the lining of the alveoli. It is mainly caused by frequent exposure to substances like asbestos, cigarette smoke, and air pollution. There are two main types of lung cancers non-small cell lung cancer NSCLC) and small cell lung cancer (SCLC) each has different properties and treatment options. Symptoms may include shortness of breath, chest pain, persistent cough and, coughing up blood.

Lung Cancer Diagnostics Market  Growth Factors

•  Technological advancements that enhance diagnostic accuracy and enable early detection and treatment are in high demand which can lead to lung cancer diagnostics market growth.
•  Increasing adoption of Non-Small Cell Lung Cancer Diagnostics methods can propel market growth shortly.
•  Increasing investments in research and development for early screening can drive market growth further.

Role of AI in lung cancer diagnostics

Artificial Intelligence (AI) can analyze CT scans to detect symptoms associated with lung cancer and analyze a patient's risk of developing lung cancer in the futrue.AI can also be utilised to help radiologists interpret CT scans. Furthermore, AI can find patterns in DNA fragments in the blood that are related to lung cancer. This can directly lead to detecting lung cancer at an early stage and can also help recommend probable drug candidates for further treatment.

•  In May 2024, Lucem Health, a leader in AI-driven early disease detection solutions, announced the introduction of Reveal for Lung Cancer. This innovative new solution aims to help the healthcare system enhance the identification and engagement of patients at a higher statistical risk for certain respiratory illnesses, such as cancers of the lung or trachea, facilitating earlier diagnosis and treatment.

Market Scope

Market Dynamics

Driver

Increasing awareness of early detection and screening

As public education campaigns increase awareness about potential risk factors for lung cancer such as environmental pollutants and smoking, peoples are more anticipated to look for preventive healthcare measure like regular screenings. Additionally, the advocacy efforts by various medical organizations can further optimize awareness prompting medical providers to prioritize lung cancer diagnosis and screening in their practice.

• In October 2024, the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc and the American Lung Association, are partnered to launch a pioneering initiative to change lung cancer screening and detection in Florida.

Restraint

Availability of Alternative Diagnostic Methods

The availability of more cost-effective and accessible alternative diagnostic practices can impact market growth negatively. Some potential alternative diagnostic methods are NGS sequencing, Blood-based screening, and Targeted DNA enrichment methods. However, most current diagnostic techniques only detect lung cancer in a much-advanced stages, when cure and treatment may not be that effective.

Opportunity

Increasing Demand for Specialized Diagnostic Solutions

The risk of developing lung cancer rises as people age fuelling the demand for screening programs and diagnostic tests specific to ageing population. The elderly population often witnesses comorbidities and has unique healthcare requirements. Furthermore, the increasing geriatric population in many regions, especially in developed countries creates a lucrative opportunity for lung cancer diagnostics.

• In June 2023, The University of New Mexico Comprehensive Cancer Center unveiled a new comprehensive lung cancer screening clinic as part of the institution’s lung cancer screening program. Lung cancer is one of the deadliest cancers,” Balwan, a UNM pulmonologist, said.

Type Insights

The non-small cell lung cancer (NSCLC) segment led the lung cancer diagnostics market in 2023. The dominance of the segment can be attributed to the increasing need for targeted drug therapy, imaging, and immunotherapy treatment options. NSCLC is further categorised into adenocarcinoma, squamous cell carcinoma and large cell carcinoma. In addition, NSCLC is the most common kind of lung cancer that takes place in people who have a long history of smoking.

• In October 2024, Merck have announced the commencement of a Phase 3 clinical trial, INTerpath-009, to evaluate the efficacy of V940 (mRNA-4157) in conjunction with KEYTRUDA® (pembrolizumab) as an adjuvant treatment for patients with resect able non-small cell lung cancer (NSCLC).

The small-cell lung cancer (SCLC) is expected to grow at the fastest rate over the forecast period. The growth of the segment can be linked to the growing technological developments in SCLC treatment options such as biopsy, imaging, and bronchoscopy. SCLSC is further categorized into small-cell carcinoma and combined small-cell carcinoma. Patients who have shared history of disease in the family are more prone to developed SCLC conditions.

Test Insights

The EGFR mutation tests segment dominated the lung cancer diagnostics market in 2023.The dominance of the segment can be credited to the increasing demand for biomarker testing, treatment options and clinical assessment for EGFR. Untreated EGFR rapidly incorporates the tumour cells in the individuals, which is a factor for the occurrence of lung cancer in people irrespective of their stage. Moroever, ,liquid biopsy has increasingly become convenient tool l in metastatic settings.

The HER2 test segment is anticipated to grow at the fastest rate during the forecast period. the HER2 test measures the quantity of the human epidermal growth factor receptor 2 (HER2) protein in a cancer cell. HER2 is a protein that controls cell growth and differentiation for normal cell growth.  Other treatment solutions like pills that inhibit HER2 from growing in the body are gaining traction among healthcare professionals, leading to segment growth further.

•  In May 2024, FDA approves trastuzumab deruxtecan for any HER2-positive solid cancer. The drug trastuzumab deruxtecan (Enhertu) can now be used to treat a wide variety of cancers. The approval makes T-DXd the first cancer therapy of its type, an antibody─drug conjugate, that can be utilised in such a “tumor agnostic” manner.

End Use Insights

In 2023, the hospitals and clinics segment led the lung cancer diagnostics market by holding largest market share. The dominance of the segment can be driven by facilities with advanced imaging technologies and superior diagnostic tools offered by hospitals and clinics for precise detection of lung cancer. Furthermore, they also possess multidisciplinary groups of pathologists, radiologists, and oncologists to achieve treatment goals. This segment is the main facility for administering complicated treatments including chemotherapy and surgical procedures.

The diagnostic laboratories segment is anticipated to show the fastest growth over the projected period. The growth of the segment can be linked to the increasing contribution of the laboratories in detecting and treating cancer coupled with the personalised treatment plan offered by them based on the patient profile. The laboratory tests comprise ultrasound, X-rays, MRI & CT scans, and PET scans among others.

Lung Cancer Diagnostics Market Companies

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific
• Illumina Inc
• Agilent Technologies
• Qiagen
• Abbott
• Bio-Rad
• Neogenomics Laboratories
• bioMérieux
• Myriad Genetics, Inc

Latest Announcements by Industry Leaders

•  In July 2024, the CEO of Roche Diagnostics commented that, access to diagnostic testing is critical for the delivery of healthcare globally and we are confident that the LumiraDx platform and technology will help us in case the availability of testing, especially in settings such as primary care and low and middle-income countries.

Recent Developments

•  In March 2023, Agilent Technologies Inc. acquired Resolution Bioscience Inc. to expand the NGS-based cancer treatment capabilities. This acquisition further boosts Agilent's position in the cancer diagnostics market.
•  In March 2023, Roche declared approval from the U.S. FDA for VENTANA PD-L1 (SP263) Assay. SP263 helps in advising immunotherapy non-small cell lung cancer (NSCLC) patients.
•  In October 2022, Quest Diagnostics embarked on a renewed collaboration with Decode Health, marking a new phase in their partnership. 
• In August 2022, F. Hoffmann-La Roche Ltd. launched the Digital LightCycler System, a cutting-edge digital PCR system aiding clinical researchers in comprehending cancer, genetic diseases, and infections.

Segments Covered in the Report

By Type 

• Non-small cell lung cancer
•  Small cell lung cancer

By Test 

• CA test
•  HER2 test
•  ALK test
•  Angiogenesis Inhibitors
•  EGFR Mutation test
• KRAS Mutation test

By End Use

• Hospitals and clinics
•  Diagnostic Laboratories
•  Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa